Retour

Watch Compare

Sensei Biotherapeutics, Inc.

Qualité des données : 83%

SNSE

NASDAQ Manufacturing Chemicals

29,21 €

▲ 0,51 € (1,78%)

6 months return

—

Momentum

Neutral

ROE

-83,80%

Croissance

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

-83,80%

En dessous de la moyenne du secteur (-54,47%)

ROIC-68,96%

Net MarginN/A

Op. MarginN/A

Sécurité

Debt / Equity

N/A

Current Ratio5,81

Interest Coverage-696,50

Valorisation

PE (TTM)

-1,95

En dessous de la moyenne du secteur (-1,50)

P/B Ratio1,79

EV/EBITDAN/A

Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -20,47 M

Price History

Tendances Financières

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Surprises de Résultats

EPS

Reported Estimate Forecast

Next: Q2 2026 · Rev Est: 0,0

	Q12025	Q22025	Q32025	Q42025	Q2 '26
Reported	-5,40 €	-3,91 €	-3,62 €	-3,74 €	—
Estimate	-5,20 €	-5,00 €	-4,11 €	-4,81 €	—
Surprise	-3,85%	+21,80%	+11,92%	+22,25%	—

Growth

Rev 5Y: N/A · Earnings 1Y: N/A

Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A

Profitability

ROE: -83,80% · Net Margin: N/A

Revenue (TTM)	N/A	Net Income (TTM)	-21,09 M
ROE	-83,80%	ROA	-71,03%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-20,47 M
ROIC	-68,96%	FCF Growth (3Y)	N/A

Safety

D/E: N/A · Current: 5,81

Debt / Equity	N/A	Current Ratio	5,81
Interest Coverage	-696,50	Asset Turnover	N/A
Working Capital	21,35 M	Tangible Book Value	23,01 M

Dividends

Yield: N/A · Payout: N/A

Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A

Valuation

P/E: -1,95 · EV/EBITDA: N/A

P/E Ratio	-1,95	Forward P/E	N/A
P/B Ratio	1,79	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-49,75%
Market Cap	41,15 M	Enterprise Value	30,58 M

Per Share

EPS: -16,72 · FCF/Share: -15,27

EPS (Diluted TTM)	-16,72	Revenue / Share	N/A
FCF / Share	-15,27	OCF / Share	-15,26
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A

Efficiency

FCF Conv: 97,08% · CapEx/Rev: N/A

CapEx / Revenue	N/A	FCF Conversion	97,08%
SBC-Adj. FCF	-22,18 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	—	—	—
Net Income	-21,09 M	-30,16 M	-34,10 M	-48,59 M	-36,79 M
EPS (Diluted)	-16,72	-1,20	-1,22	-1,58	—
Gross Profit	—	—	—	—	—
Operating Income	-22,29 M	-32,61 M	-37,06 M	-50,19 M	-37,48 M
EBITDA	—	—	—	—	—
R&D Expenses	—	—	—	—	—
SG&A Expenses	—	—	—	—	—
D&A	122 000,0	551 000,0	571 000,0	614 000,0	685 000,0
Interest Expense	32 000,0	90 000,0	144 000,0	219 000,0	670 000,0
Income Tax	0,0	—	—	—	—

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	22,90 M	45,36 M	74,37 M	118,38 M	153,23 M
Total Liabilities	4,31 M	6,98 M	9,48 M	14,97 M	6,71 M
Shareholders' Equity	18,59 M	38,39 M	64,90 M	103,41 M	146,51 M
Total Debt	—	—	—	—	567 000,0
Cash & Equivalents	8,67 M	9,99 M	13,01 M	17,80 M	7,16 M
Current Assets	21,51 M	41,93 M	67,25 M	108,59 M	148,54 M
Current Liabilities	4,25 M	5,45 M	5,64 M	9,07 M	4,89 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)

Métrique	Action	Médiane du Secteur
P/E	-2,0	-1,5
P/B	1,8	1,6
ROE %	-83,8	-54,5
Net Margin %	—	-41,5
Rev Growth 5Y %	—	1,7
D/E	—	0,3